ArticlePolymers2021
Nanocomposite Cellulose Fibres Doped with Graphene Oxide and Their Biocidal Properties.
Article in Polymers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Exploring the Antimicrobial Efficacy of Graphene Oxide: Key Mechanisms and Future Directions.Pharmaceutics · 2026Review
- Macro-Size Regenerated Cellulose Fibre Embedded with Graphene Oxide with Antibacterial Properties.Polymers · 2023Article
- Preparation of an Active Dressing by In Situ Biosynthesis of a Bacterial Cellulose-Graphene Oxide Composite.Polymers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The paper presents a method of obtaining composite cellulose fibres (CEL) doped with graphene oxide (GO) and the influence of GO nanoparticles on the structure and properties of the obtained fibres. Composite fibres (GO/CEL) were prepared using wet method from 5% CEL solutions in 1-ethyl-3-methylimidazolium acetate (EMIMAc) containing GO (0; 0.21; 0.50; 0.98; 1.97%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.